Winrevair, which Merck has identified as a “growth driver,” significantly improved blood flow through the lungs to the heart in a study of adults with a common form of heart failure.
Winrevair, which Merck has identified as a “growth driver,” significantly improved blood flow through the lungs to the heart in a study of adults with a common form of heart failure.
